0000000001005256

AUTHOR

Cabibbo G

showing 6 related works from this author

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre s…

2015

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Resul…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularLoco-regional therapieHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyCohort StudiesLiver diseaseInterquartile rangeInternal medicinemedicineHumansBest supportive care; Cirrhosis; Hepatocellular carcinoma; Liver resection; Loco-regional therapies; Survival benefit; Aged; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Treatment Outcome; Medicine (all); HepatologyBEST SUPPORTING CAREAgedNeoplasm StagingCirrhosiHepatologyPerformance statusLiver resectionbusiness.industryMedicine (all)CIRRHOISISCarcinomaLiver NeoplasmsHepatocellularMiddle Agedmedicine.diseasePrognosisBCLC StageTreatment OutcomeCirrhosisItalySurvival benefitHepatocellular carcinomaMultivariate AnalysisFemaleLoco-regional therapiesLiver cancerbusinessBest supportive careJournal of hepatology
researchProduct

Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

2011

Sorafenib (Nexavar®, Bayer), a multi-targeted tyrosine kinase inhibitor, was the first systemic agent that demonstrated a significant improvement in the overall survival in patients with advanced hepatocellular carcinoma and well-preserved liver function. This drug is now recommended in patients with advanced hepatocellular carcinoma as first-line therapy and for patients not suitable for locoregional treatment. This brief article, produced by a multidisciplinary panel including specialists in gastroenterology and oncology, provides an overview of the major issues related to systemic treatment of hepatocellular carcinoma with sorafenib, including staging and prognostic strategies, assessmen…

OncologySorafenibLiver CirrhosisNiacinamidemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.drug_classPyridinesAntineoplastic AgentsGastroenterologyTyrosine-kinase inhibitorsystemic therapyliver cancerLiver diseaseInternal medicinemedicineHumansPharmacology (medical)treatmentbusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsDisease Managementhepatocellular carcinomamedicine.diseasehepatocellular carcinoma sorafenb cirrhosisdigestive system diseasesOncologyTolerabilityHepatocellular carcinomasorafenibLiver functionLiver cancerbusinessmanagementmedicine.drugcirrhosi
researchProduct

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.

2017

Background and aims the Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumor burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while others could undergo curative treatments. This study assesses the treatment type performed in a large cohort of BCLC-B patients and its outcome. Methods retrospective analysis of 485 consecutive BCLC-B patients from the ITA.LI.CA database diagnosed with naive HCC after 1999. Patients were stratified by treatment. Results 29 patients (6%) were lost to follo…

SorafenibMaleNiacinamidemedicine.medical_specialtyStandard of careCarcinoma HepatocellularAntineoplastic AgentsGastroenterologyIntermediate stage03 medical and health sciences0302 clinical medicineHCC; BCLC-B; Intermediate stage; Treatment; HepatologyInternal medicinemedicineHumansChemoembolization TherapeuticHCCPropensity ScoreAgedNeoplasm StagingRetrospective Studiesintermediate stageHepatologytreatmentbusiness.industryPatient SelectionPhenylurea CompoundsLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAStandard of CareHepatologyMiddle AgedSorafenibmedicine.diseaseSurvival AnalysisTreatment OutcomeItaly030220 oncology & carcinogenesisHepatocellular carcinomaPropensity score matchingMultivariate Analysis030211 gastroenterology & hepatologyFemaleLiver functionLiver cancerbusinessBCLC-Bmedicine.drug
researchProduct

Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres

2013

Background & Aims Hepatitis C virus (HCV) is the leading aetiological factor of HCC in the western world where, overall, its incidence is increasing, despite data suggesting an initial drop in some areas. The aim of this study was to evaluate epidemiology, clinical features and survival of HCV-related HCC (HCV-HCC) in a wide time range in Italy. Methods Multicentre retrospective study including 3695 patients prospectively recruited by the ITA.LI.CA group. Patients were classified into three subgroups according to aetiology (Group A[GA], pure HCV; Group B[GB], HCV + cofactors; and Group C[GC], non-HCV) and in 5 time cohorts (5 years each), according to the year of diagnosis. Age, gender, Chi…

Malemedicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatitis C virushepatitis C hepatocellular carcinoma cirrhosismedicine.disease_causeGastroenterologyGroup BSex FactorsInternal medicineEpidemiologyPrevalencemedicineHumansHEPATOCELLULAR CARCINOMACIRRHOSISRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsAge FactorsRetrospective cohort studyHepatitis Cmedicine.diseaseHepatitis CSurvival Analysisdigestive system diseasesSurgeryItalyHepatocellular carcinomaEtiologyFemalebusinessLiver International
researchProduct

Circadian rhythm of COPD symptoms in clinically based phenotypes. Results from the STORICO Italian observational study

2019

Abstract Background Chronic Obstructive Pulmonary Disease (COPD) encompasses various phenotypes that severely limit the applicability of precision respiratory medicine. The present investigation is aimed to assess the circadian rhythm of symptoms in pre-defined clinical COPD phenotypes and its association with health-related quality of life (HR-QoL), the quality of sleep and the level of depression/anxiety in each clinical phenotype. Methods The STORICO (NCT03105999) Italian observational prospective cohort study enrolled COPD subjects. A clinical diagnosis of either chronic bronchitis (CB), emphysema (EM) or mixed COPD-asthma (MCA) phenotype was made by clinicians at enrollment. Baseline e…

MaleChronic bronchitisTime FactorsHealth StatusAnxietyHospital Anxiety and Depression ScaleSeverity of Illness IndexHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesForced Expiratory VolumeClinical phenotypeMedicineSurveys and QuestionnaireRespiratory function030212 general & internal medicineProspective StudiesProspective cohort studyLungDepression (differential diagnoses)COPDDepressionMiddle AgedCircadian RhythmPhenotypeItalyAnxietyFemalemedicine.symptom24-hour symptoms Clinical phenotype Real-world Respiratory functionResearch ArticleHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveTime FactorSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesInternal medicineHumansAsthma24-hour symptoms; Clinical phenotype; Real-world; Respiratory function; Aged; Anxiety; Depression; Female; Forced Expiratory Volume; Health Status; Humans; Italy; Lung; Male; Middle Aged; Phenotype; Prospective Studies; Pulmonary Disease Chronic Obstructive; Severity of Illness Index; Sleep; Surveys and Questionnaires; Time Factors; Circadian Rhythm; Quality of LifeAgedlcsh:RC705-77924-hour symptomsbusiness.industryCorrectionlcsh:Diseases of the respiratory systemmedicine.disease24-hour symptomProspective Studie030228 respiratory systemReal-worldQuality of LifebusinessSleepRespiratory function
researchProduct

Radio-frequency thermal ablation (RFTA) of small hepatocellular carcinoma in patients with cirrhosis. Experience at a single tertiary referral center

2005

AIM: Radio-frequency thermal ablation (RFTA) may prolong the survival of patients with small hepatocellular carcinoma (HCC) associated with cirrhosis. The aim of this study was to evaluate efficacy and safety of RFTA. METHODS: We performed the Kaplan-Meier analysis to estimate the survival rate in 69 consecutive patients with HCC (mean age 66+/-6.5 years; 44/25 male/female; 56 Child-Pugh class A and 13 Child-Pugh class B) treated by RFTA. A single lesion was observed in 60/69 (87%), two lesions in 8/69 (11.6 %), and 3 lesions in 1/69 (1.4 %) of patients. The tumor size was = or <3 cm in 60/69 (87%). RESULTS: Twenty-two patients died during follow-up. Overall survival rates were 81%, 66%, an…

Liver CirrhosisMaleCarcinoma Hepatocellularhepatocellular carcinoma thermal ablationLiver NeoplasmsHyperthermia InducedCancer Care FacilitiesMiddle AgedSurvival AnalysisDisease-Free SurvivalTreatment OutcomeItalyCatheter AblationHumansFemaleProspective StudiesAged
researchProduct